Europlasma (France) Probability of Future Stock Price Finishing Over 10.17
| ALEUP Stock | EUR 0.06 0.03 97.75% |
Europlasma |
Europlasma Target Price Odds to finish over 10.17
The tendency of Europlasma Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over € 10.17 or more in 90 days |
| 0.06 | 90 days | 10.17 | close to zero percent |
Based on a normal probability distribution, the odds of Europlasma to move over € 10.17 or more in 90 days from now is close to zero percent (This Europlasma SA probability density function shows the probability of Europlasma Stock to fall within a particular range of prices over 90 days) . Probability of Europlasma SA price to stay between its current price of € 0.06 and € 10.17 at the end of the 90-day period is about 82.83 .
Assuming the 90 days trading horizon Europlasma SA has a beta of -4.43. This suggests as returns on its benchmark rise, returns on holding Europlasma SA are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Europlasma is expected to outperform its benchmark. Additionally Europlasma SA has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Europlasma Price Density |
| Price |
Predictive Modules for Europlasma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Europlasma SA. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Europlasma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Europlasma is not an exception. The market had few large corrections towards the Europlasma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Europlasma SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Europlasma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.52 | |
β | Beta against Dow Jones | -4.43 | |
σ | Overall volatility | 0.05 | |
Ir | Information ratio | -0.07 |
Europlasma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Europlasma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Europlasma SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Europlasma SA generated a negative expected return over the last 90 days | |
| Europlasma SA has high historical volatility and very poor performance | |
| Europlasma SA has some characteristics of a very speculative penny stock | |
| Europlasma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Europlasma SA has accumulated 2.92 M in total debt with debt to equity ratio (D/E) of 769.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Europlasma SA has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Europlasma until it has trouble settling it off, either with new capital or with free cash flow. So, Europlasma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Europlasma SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Europlasma to invest in growth at high rates of return. When we think about Europlasma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 9.8 M. Net Loss for the year was (12.67 M) with profit before overhead, payroll, taxes, and interest of 5.65 M. | |
| Europlasma SA has accumulated about 3.92 M in cash with (18.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. |
Europlasma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Europlasma Stock often depends not only on the future outlook of the current and potential Europlasma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Europlasma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.9 T | |
| Cash And Short Term Investments | 2.5 M |
Europlasma Technical Analysis
Europlasma's future price can be derived by breaking down and analyzing its technical indicators over time. Europlasma Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Europlasma SA. In general, you should focus on analyzing Europlasma Stock price patterns and their correlations with different microeconomic environments and drivers.
Europlasma Predictive Forecast Models
Europlasma's time-series forecasting models is one of many Europlasma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Europlasma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Europlasma SA
Checking the ongoing alerts about Europlasma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Europlasma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Europlasma SA generated a negative expected return over the last 90 days | |
| Europlasma SA has high historical volatility and very poor performance | |
| Europlasma SA has some characteristics of a very speculative penny stock | |
| Europlasma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Europlasma SA has accumulated 2.92 M in total debt with debt to equity ratio (D/E) of 769.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Europlasma SA has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Europlasma until it has trouble settling it off, either with new capital or with free cash flow. So, Europlasma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Europlasma SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Europlasma to invest in growth at high rates of return. When we think about Europlasma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 9.8 M. Net Loss for the year was (12.67 M) with profit before overhead, payroll, taxes, and interest of 5.65 M. | |
| Europlasma SA has accumulated about 3.92 M in cash with (18.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. |
Additional Tools for Europlasma Stock Analysis
When running Europlasma's price analysis, check to measure Europlasma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Europlasma is operating at the current time. Most of Europlasma's value examination focuses on studying past and present price action to predict the probability of Europlasma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Europlasma's price. Additionally, you may evaluate how the addition of Europlasma to your portfolios can decrease your overall portfolio volatility.